Orell Füssli Group has acquired a majority stake in hep Verlag and becomes the largest private Swiss publisher of learning media. The complementary portfolios of both companies offer ideal conditions for positioning themselves as leading providers in the education market for learning content and for decisively shaping the digital transformation in the learning media sector […]
Tags : Marco Sibold
Kellerhals Carrard acts as lead Swiss legal and tax counsel to Ameliora Wealth Management in the acquisition of the Swiss offshore business of UBP Investment Advisors with American private clients. With this transaction, UBP, the Geneva-based private bank, has found a buyer for its Swiss business with US clients. The transaction is expected to be completed […]
Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, in the closing of its previously announced business combination with Helix Acquisition Corp. (“Helix”), a publicly traded special purpose acquisition company. The business combination was unanimously approved by Helix’s board of directors and was approved […]
Helix Acquisition Corp, a Nasdaq-listed special purpose acquisition company and MoonLake Immunotherapeutics, a Swiss based clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases agreed on a business combination. At closing of the envisaged business combination, MoonLake will have access to approximately USD 230 million in cash (subject to redemptions), […]
Kellerhals Carrard has acted as legal counsel to Stille, a medical device company, in acquiring all shares in Switzerland-based S&T, a manufacturer of microsurgical instruments, in exchange for CHF 6 million paid in cash upon completion of the transaction and financed through Stille’s existing cash liquidity and bank loans. In addition to, CHF 2.5 million […]
MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseaseshas closed a Series A financing round, lead by BVF Partners LP. Other investors included Merck KGaA, Darmstadt, Germany. MoonLake Immunotherapeutics was established by an international team of immunology specialists to create next-level therapies for inflammatory skin and joint […]
